Paclitaxel injectable suspension - ZY Therapeutics
Alternative Names: Biodegradable polysaccharides based paclitaxel - ZY Therapeutics; Biodegradable polysaccharides based paclitaxel nanoformulation - ZY Therapeutics; Paclitaxel nanoformulation - ZY Therapeutics; ZY-010-PNPLatest Information Update: 15 Jan 2022
At a glance
- Originator ZY Therapeutics
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral, Suspension)
- 26 Apr 2019 Chemical structure information added
- 03 Apr 2019 Preclinical pharmacodynamics and pharmacokinetic data in Ovarian cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)